緑内障：疫学予測（～2033年）

当レポートでは、主要8市場（米国、フランス、ドイツ、イタリア、スペイン、英国、日本）における緑内障について調査分析し、緑内障のリスク因子や併存疾患、過去の疫学的動向に関する情報を提供しています。

目次

第1章 緑内障：エグゼクティブサマリー

• カタリスト
• 関連レポート
• 今後のレポート

第2章 疫学

• 疾患の背景
• 危険因子と併存疾患
• 世界と過去の動向
• 主要7市場の予測手法
• 緑内障の疫学的予測（2023年～2033年）
  • POAG（NTGを除く）と診断された有病者
  • POAG（NTGを除く）と診断された有病者：年齢別
  • POAG（NTGを除く）と診断された有病者：性別
  • NTGと診断された有病者
  • PACGと診断された有病者
  • PACGと診断された有病者：年齢別
  • PACGと診断された有病者：性別
  • 急性/慢性PACGと診断された有病者
  • 急性PACGと診断された発症者
  • 続発性緑内障と診断された発症者
• 議論
  • 疫学的予測の考察
  • COVID-19の影響
  • 分析の限界
  • 分析の強み

第3章 付録

List of Tables

• Table 1: Summary of updated data types
• Table 2: Risk factors and comorbidities for glaucoma

List of Figures

• Figure 1: 7MM, diagnosed prevalent cases of POAG (including NTG), both sexes, N, ages >=40 years, 2023 and 2033
• Figure 2: 7MM, diagnosed prevalent cases of POAG (excluding NTG), both sexes, N, ages >=40 years, 2023 and 2033
• Figure 3: 7MM, diagnosed prevalent cases of PACG, both sexes, N, ages >=40 years, 2023 and 2033
• Figure 4: 7MM, diagnosed prevalence of POAG (including NTG), both sexes, %, ages >=40 years, 2023
• Figure 5: 7MM, diagnosed prevalence of POAG (excluding NTG), both sexes, %, ages >=40 years, 2023
• Figure 6: 7MM, diagnosed prevalence of PACG, both sexes, %, ages >=40 years, 2023
• Figure 7: 7MM, sources used and not used to forecast the diagnosed prevalent cases of POAG (excluding NTG)
• Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of NTG
• Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of PACG
• Figure 10: 7MM, sources used to forecast the diagnosed incident cases of acute PACG
• Figure 11: 7MM, sources used to forecast the diagnosed prevalent cases of secondary glaucoma
• Figure 12: 7MM, diagnosed prevalent cases of POAG (excluding NTG), N, both sexes, ages >=40 years, 2023
• Figure 13: 7MM, diagnosed prevalent cases of POAG (excluding NTG) by age, N, both sexes, 2023
• Figure 14: 7MM, diagnosed prevalent cases of POAG (excluding NTG) by sex, N, ages >=40 years, 2023
• Figure 15: 7MM, diagnosed prevalent cases of NTG, N, both sexes, ages >=40 years, 2023
• Figure 16: 7MM, diagnosed prevalent cases of PACG, N, both sexes, ages >=40 years, 2023
• Figure 17: 7MM, diagnosed prevalent cases of PACG by age, N, both sexes, 2023
• Figure 18: 7MM, diagnosed prevalent cases of PACG by sex, N, both sexes, ages >=40 years, 2023
• Figure 19: 7MM, diagnosed prevalent cases of acute and chronic PACG, N, both sexes, ages >=40 years, 2023
• Figure 20: 7MM, diagnosed incident cases of acute PACG, N, both sexes, ages >=40 years, 2023
• Figure 21: 7MM, diagnosed prevalent cases of secondary glaucoma, N, both sexes, ages >=40 years, 2023

Glaucoma is a group of progressive neurodegenerative eye diseases caused by damage to the optic nerve (Manz et al., 2024). Globally, glaucoma is the leading cause of blindness and vision loss, and it has a significant impact on quality of life (Fujiwara et al., 2022) Glaucoma is categorized as primary open-angle glaucoma (POAG), normal tension glaucoma (NTG), primary angle-closure glaucoma (PACG), chronic angle-closure glaucoma, acute angle-closure glaucoma, and secondary glaucoma. Open-angle glaucoma is classified as high-tension glaucoma (HTG) if intraocular pressure (IOP) is greater than 21mm HG, and as NTG if IOP is less than 21mm HG. OAG in this report represents OAG with HTG, which is responsible for 80-90% of all glaucoma cases (Chan et al., 2017).

Scope

• This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for glaucoma in the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan).
• The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of POAG and PACG, segmented by age and sex (40-44 years, 45-49 years, 50-54 years, 55-59 years, 60-64 years, 65-69 years, 70-74 years, 75-79 years, 80-84 years, and >=85 years) in the 7MM.
• In addition, this report provides a 10-year epidemiology forecast of the diagnosed prevalent cases of the clinical types of glaucoma: NTG, acute and chronic PACG, secondary glaucoma, and the diagnosed incident cases of PACG.
• Although not covered in this report, the diagnosed prevalence of pigmentary glaucoma and pseudoexfoliation glaucoma can be found in the associated glaucoma model, as well as the total prevalence of POAG (excluding NTG) and PACG.

Reasons to Buy

The glaucoma Epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global glaucoma markets.
• Quantify patient populations in the global glaucoma markets to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for glaucoma therapeutics in each of the markets covered.
• Understand magnitude of the glaucoma population by age, sex, type, and infection site.

Table of Contents

Table of Contents

• About GlobalData

1 Glaucoma: Executive Summary

• 1.1 Catalyst
• 1.2 Related Reports
• 1.3 Upcoming Reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities
• 2.3 Global and historical trends
• 2.4 7MM forecast methodology
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods
  • 2.4.3 Forecast assumptions and methods: diagnosed prevalent cases of POAG (excluding NTG)
  • 2.4.4 Forecast assumptions and methods: diagnosed prevalent cases of NTG
  • 2.4.5 Forecast assumptions and methods: diagnosed prevalent cases of PACG
  • 2.4.6 Forecast assumptions and methods: diagnosed incident cases of acute PACG
  • 2.4.7 Forecast assumptions and methods: diagnosed prevalent cases of secondary glaucoma
• 2.5 Epidemiological forecast for glaucoma (2023-33)
  • 2.5.1 Diagnosed prevalent cases of POAG (excluding NTG)
  • 2.5.2 Age-specific diagnosed prevalent cases of POAG (excluding NTG)
  • 2.5.3 Sex-specific diagnosed prevalent cases of POAG (excluding NTG)
  • 2.5.4 Diagnosed prevalent cases of NTG
  • 2.5.5 Diagnosed prevalent cases of PACG
  • 2.5.6 Age-specific diagnosed prevalent cases of PACG
  • 2.5.7 Sex-specific diagnosed prevalent cases of PACG
  • 2.5.8 Diagnosed prevalent cases acute and chronic PACG
  • 2.5.9 Diagnosed incident cases of acute PACG
  • 2.5.10 Diagnosed incident cases of secondary glaucoma
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 COVID-19 impact
  • 2.6.3 Limitations of the analysis
  • 2.6.4 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 About the Authors
  • 3.2.1 Epidemiologist
  • 3.2.2 Reviewers
  • 3.2.3 Vice President of Disease Intelligence and Epidemiology
  • 3.2.4 Vice President of Disease Intelligence and Epidemiology
• Contact Us